# FORM PTO-1449 U.S. DEPARTMENT F COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET ...

SER. NO.

97-092-US

08/833,842

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT KAESEMEYER

FILING DATE

**GROUP ART UNIT** 

April 10, 1997

1614

(37 CFR 1.98(b))

#### **U.S. PATENT DOCUMENTS**

Examiner Initial	Patent Number	Issue Date	Patentee	Class/ Subclass	Filing Date
101	5,543,430 -	Aug. 6, 1996	Kaesemeyer	519/565	F
A.	5,428,070	Jun. 27, 1995	Cooke et al.	514 557	
	5,316,765	May 31, 1994	Folkers et al.	424/44.1	1.13
<del></del>	5,196,195	Mar. 23, 1993	Griffith	424/94.6	
	5,158,883	Oct. 27, 1992	Griffith	435 240.2	
	5,132,453	Jul. 21, 1992	Griffith	562 560	
	5,059,712	Oct. 22, 1991	Griffith	562   560	
180	4,686,211	Aug. 11, 1987	Hara et al.	514/142	

### OTHER DOCUMENTS

(Including Author, Title, Date, Relevant Pages, Place of Publication)

		the state of the s
Examiner Įnitial		
	AA	Patel, J. M. et al. <u>Nitric Oxide Exposure and Sulfhydryl Modulation Alter L-Arginine Transport in Cultured Pulmonary Artery Endothelial Cells</u> . (Abstract Only) Free Radical Biology & Medicine. Vol. 20, No. 5. pp. 629. 1996.
	AB ,	Xia, Y. et al. <u>Nitric Oxide Synthase Generates Superoxide and Nitric Oxide in Arginine-Depleted</u> <u>Cells Leading to Peroxynitrite-Mediated Cellular Injury</u> . Proc. Natl. Acad. Sci. USA. Vol. 93. pp. 6770-6774. June 1996.
	AC	Jeremy, R. W. et al. Effects of Dietary L-Arginine on Atherosclerosis and Endothelium- Dependent Vasolidation in the Hypercholesteralemic Rabbit. Circulation. Vol. 94, No. 3. pp. 498-506. August 1, 1996.
	AD	Block, E. R. et al. <u>Hypoxia Inhibits L-Arginine Uptake By Pulmonary Artery Endothelial Cells</u> . (Abstract Only) Am. J. Physiol. Vol. 269. L574-L580. 1995.
Am .	AE	Mayer, B. et al. <u>Brain Nitric Oxide Synthase is a Biopterin-and Flavin-Containing Multi-Functional Oxido-Reductase</u> . (Abstract Only) FEBS 10045. Vol. 288, No. 1,2. pp. 187-191. August 1991.
	AF	Weidinger, F. F. et al. <u>Persistent Dysfunction of Regenerated Endothelium After Balloon</u> <u>Angioplasty of Rabbit Iliac Artery</u> . Circulation. Vol. 81, No. 5. pp. 1667-1679. May 1990.
		DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considere

Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 97-092-US	SER. NO. 08/833,842
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT KAESEMEYER	
	FILING DATE	GROUP ART UNIT
(37 CFR 1.98(b))	April 10, 1997	1614

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

		(including Author, Title, Date, Relevant Lages, Flace of Labillation)		
Examiner				
initial				
	BA	Chester, A. H. et al. Low Basal and Stimulated Release of Nitric Oxide in Atherosclerotic Epicardial Coronary Arteries. The Lancet. Vol. 336. pp. 897-900. Oct. 13, 1990.		
	вв	Albina, J. E. et al. <u>Arginine Metabolism in Wounds</u> . Am. J. Physiol. Vol. 254. pp. E459-E467. 1988.		
100	вс	Cooke, J.P. et al. <u>Antiatherogenic Effects of L-Arginine in the Hypercholesterolemic Rabbit</u> . (Abstract Only) J. Clin. Invest. Vol. 90, No. 3. pp. 1168-72. Sep. 1992.		
	BD	Nakamura, Y. et al. <u>Pravastatin Reduces Restenosis After Coronary Angioplasty of High Grade Stenotic Lesions: Results of SHIPS (SHIga Pravastatin Study)</u> . (Abstract Only). Cardiovasc. Drugs. Ther., Vol. 10, No. 4, pp. 475-483. 1996.		
	BE	Pohl, U. et al. Effects of LDL on Intracellular Free Calcium and Nitric Oxide-Dependent cGMP Formation on Porcine Endothelial Cells. (Abstract only) Atherosclerosis. Vol. 117. pp. 169-178. 1995.		
	BF	Deliconstantinos, G. et al. <u>Modulation of Particulate Nitric Oxide Synthase Activity and Peroxynitrate Synthesis in Cholesterol Enriched Endothelial Cell Membranes</u> . (Abstract Only) Biochem. Pharm. Vol. 49. No. 11. pp. 1589-1600. 1995.		
	BG	Galle, J. et al. Effect of HDL and Atherogenic Lipoproteins on Formation of O <sub>2</sub> and Renin Release in Juxtaglomerular Cells. (Abstract Only) Kidney International. Vol. 51. pp. 253-260. 1997.		
	вн	Bult, H. <u>Nitric Oxide and Atherosclerosis: Possible Implications for Therapy</u> . (Abstract only) Molecular Medicine Today. p. 510. December 1996.		
	ВІ	Crouse III, J.R. et al. <u>Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)</u> . (Abstract only) Am. J. Cardiol. Vol. 75. pp. 455-459. 1995.		
	BJ	Aji, W. et al. <u>L-Arginine Prevents Xanthoma Development and Inhibits Atherosclerosis in LDL Receptor Knockout Mice</u> . (Abstract only) Circulation. Vol. 95. pp. 430-437. 1997.		
	вк	Cooke, J. P. et al. <u>Arginine: A new Therapy for Atherosclerosis?</u> . Circulation. Vol. 95. pp. 311-12. 1997.		
	BL	Boger, R. H. et al. <u>The L-Arginine Nitric Oxide Pathway: Role in Atherosclerosis and Therapeutic Implications</u> . (First page only) Atherosclerosis. Vol. 127. pp. 1-11. 1996.		
		DATE CONSIDERED		
	august 3, 1991			

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 97-092-US	SER. NO. 08/833,842
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT KAESEMEYER	
	FILING DATE	GROUP ART UNIT
(37 CFR 1.98(b))	April 10, 1997	1614

### **OTHER DOCUMENTS** (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial			
	CA	Jay, M.T. et al. <u>Modulation of Vascular Tone By Low Density Lipoproteins</u> <u>Transport and Nitric Oxide Synthesis.</u> Experimental Physiology. Vol. 82.	s. Effects on L-Arginine op. 349-360. 1997.
		Muramatsu, J. et al. <u>Hemodynamic Changes Associated with Reduction i Treatment with the HMG-CoA Reductase Inhibitor Pravastatin.</u> Atherosci. 179-182. 1997.	n Total Cholesterol By erosis. Vol. 130. pp.
	СС	Sacks, F. M. et al. <u>The Effect of Pravastatin on Coronary Events After My Patients with Average Cholesterol Levels.</u> The New England Journal of M 1001-1009. October 3, 1996.	ocardial Infarction in ledicine. Vol. 335. pp.
No	CD	Bovan, A. J. van. et al. <u>Reduction of Transient Myocardial Ischemia with to the Conventional Treatment in Patients with Angina Pectoris.</u> Circulation 1505. 1996.	Pravastatin in Addition on. Vol. 94. pp. 1503-
	CE	Lacoste, L. et al. <u>Comparative Effect of Pravastatin and Simvastatin on P</u> <u>Formation in Hypercholesterolemic Coronary Patients.</u> JACC. Vol. 27 No 1996.	<u>latelet-Thrombus</u> . 2 Supp A. p. 413A.
	CF	Pitt, B. et al. <u>Pravastatin Limitation of Atherosclerosis in the Coronary Art Reduction in Atherosclerosis Progression and Clinical Events</u> . J. Am. Col 1133-9. 1995.	eries (PLAC I): I. Cardiol. Vol. 26. pp.
All I	CG	Candipan, R.C. et al. <u>Regression or Progression: Dependency on Vascul</u> Arterioscler. Thromb. Vas. Biol. Vol. 16. pp. 44-50. 1996.	ar Nitric Oxide.
	СН	Byington, R.P. et al. <u>Reduction in Cardiovascular Events During Pravasta Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention</u> Vol. 92. pp. 2419-2425. 1995.	atin Therapy. Pooled  Program. Circulation.
	CI	Pritchard, K.A. et al. <u>Native Low-Density Lipoprotein Increases Endotheli</u> <u>Synthase Generation of Superoxide Anion</u> . Circ. Res. Vol. 77 No. 3. pp. 5	<u>al Cell Nitric Oxide</u> 510-518. 1995.
	C1	Boger, R.H. et al. <u>Supplementation of Hypercholesterolemic Rabbits with Vascular Release of Superoxide Anions and Restores NO Production</u> . Ar No. 2. pp. 273-284. 1995.	L-Arginine Reduces the therosclerosis. Vol. 117
	1		DATE CONSIDERED
		MA	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SER. NO.
(MODIFIED) PATERTARD TRADEMARKOTTIOE	97-092-US	08/833,842
	APPLICANT	<u> </u>
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	KAESEMEYER	
	FILING DATE	GROUP ART UNIT
	April 10, 1997	1614
(37 CFR 1.98(b))		

## OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

		(iliciddling Additor, Title, Date, Relevant rages, Flace of rabilication)
Examiner		
Mitial		
	DA	Lacoste, L. et al. <u>Correction of the Increased Thrombogenic Potential with Cholesterol Reduction</u> . Circulation. Vol 92. pp. 3172-3177. 1995.
	DB	Shepard, J. <u>Prevention of Coronary Heart Disease with Provastatin in Men with</u> <u>Hypercholestrolemia</u> . The New England Journal of Medicine Vol. 333. pp. 1301-1307. November 16, 1995.
	DC	Philis-Tsimikas, A. et al. <u>L-Arginine May Inhibit Atherosclerosis Through Inhibition of LDL Oxidation</u> . Circulation. Vol. 92 (Supp. I). pp. I-422. 1995.
	DD	Von der Leyen, H.E. et al. <u>Gene Therapy Inhibiting Neointimal Vascular Lesion: In Vivo Transfer of Endothelial Cell Nitric Oxide Synthase Gene</u> . Proc. Natl. Acad. Sci. USA. Vol. 92. pp. 1137-1141. 1995.
	DE	Egashira, K. et al. Reduction in Serum Cholesterol with Pravastatin Improves Endothelium- Dependent Coronary Vasomotion in Patients with Hypercholesterolemia. Circulation. Vol. 89. pp. 2519-2524. 1994.
	DF	Tsao, P. et al. <u>Enhanced Endothelial Adhesiveness in Hypercholesterolemia is Attenuated by L-Arginine</u> . Circulation. Vol. 89. pp. 2176-2182. 1994.
	DĞ	Cayatte, A.J. et al. <u>Chronic Inhibition of Nitric Oxide Production Accelerates Neointima</u> <u>Formation and Impairs Endothelial Function in Hypercholesterolemic Rabbits</u> . Arterioscler. Thomb. Vol. 14. pp. 753-759. 1994.
	DH	Wilcox, J.N. et al. <u>Expression of Multiple Nitric Oxide Synthase Isoforms in Human Aortic Fatty Streaks and Advanced Atherosclerotic Plaques</u> . (Abstract only) Circulation. Vol. 90 (Supp. I). pp. I-298. 1994.
	DI	Chen, L. Y. et al. Oxidated LDL Decreases L-Arginine Uptake and Nitric Oxide Synthase Protein Expression in Human Platelets: Relevance of the Effect of Oxidized LDL on Platelet Function. Circulation. Vol. 93. pp. 1740-1746. 1993.
	DJ	Wada, H. et al. <u>Hypercoagulable State in Patients with Hypercholesterolemia: Effects of Pravastatin</u> . Clin. Therap. Vol. 14. pp. 829-34. 1992.
	DK	Dresler, H. et al. <u>Correction of Endotelial Dysfunction in Coronary Microcirculation of Hypercholesterolaemia Patients by L-Arginine</u> . The Lancet. Vol. 338. pp. 1546-1550. Dec. 21/28, 1991.
		DATE Tugut 3,1997 CONSIDERED

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 97-092-US	SER. NO. 08/833,842
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT KAESEMEYER	
•	FILING DATE	GROUP ART UNIT
	April 10, 1997	1614
(37 CFR 1.98(b))		

### OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner		
hitial		
	EA	Haman, M. et al. <u>Long-Term Oral Administration of L-Arginine Reduces Intimal Thickening and Enhances Neoendothelium-Dependent Acetylcholine-Induced Relaxation After Arterial Injury</u> . Circulation, Vol. 90. No. 3, pp. 1357-1362. September, 1994.
	EB	Harrison, D.G. Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis. J. Am. Coll. Cardiol. Vol. 17. pp. 71B-6B. 1991.
	EC	Cooke, J.P. et al. <u>Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta</u> . Circulation. Vol. 83. pp. 1057-1062. 1991.
	ED	Witzum, J.L. et al. <u>Role of Oxidized Low Density Lipoprotein in Atherogenesis</u> . J. Clin. Invest. Vol. 88. pp. 1785-1792. 1991.
	EE	Mugge, A.J. et al. <u>Chronic Treatment with Polyethylene-Glycolated Superoxide Dismutase</u> <u>Partially Restores Endothelium-Dependent Vascular Relaxations in Cholesterol-Fed Rabbits.</u> Circ. Res. Vol. 69. pp. 1293-1300. 1991.
	EF	Forstermann, U. et al. <u>Selective Attenuation of Endothelium-Mediated Vasodilation in Atherosclerotic Human Coronary Arteries</u> . Circ. Res. Vol. 62. pp. 185-191. 1988.
AND THE RESERVE TO TH	EG	Cohen, R.A. et al. Loss of Selective Endothelial Cell Vasoactive Functions in Pig Coronary Arteries During Hypercholesterolemia. Circ. Res. Vol. 63. pp. 903-910. 1988.
	EH	Schwarzacher, A.P. et al. <u>Locak Intramural Delivery of L-Arginine Enhances Nitric Oxide</u> <u>Generation and Inhibit Lesion Formation After Balloon Angioplasty</u> . Circulation, Vol. 95. No. 7. pp. 1863-1869. April 1, 1997.
	EI	Verbeuren, T.J. et al. Effect of Hypercholesterolemia on Vascular Reactivity in the Rabbit., I:  Endothelium-Dependent and Independent Contractions and Relaxations in Isolated Arteries of Control and Hypercholesterolemic Rabbits. Circ. Res. Vol. 58. pp. 552-564. 1986.
		DATE
	٨	CONSIDERED
	Thin	Muguet 3,1997
	C	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 97-092-US	SER. NO. 08/833,842
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT KAESEMEYER	
(37 CFR 1.98(b))	FILING DATE April 10, 1997	GROUP ART UNIT 1614
(37 CFR 1.98(D))		

# OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner , lipitiai		
	FA	Duggan, D.E. et al. <u>The Physiological Disposition of Lovastatin</u> . Drug Metabolism and Disposition, Vol. 17, No. 2. pp. 166-173. 1989.
	FB	Vickers, S. et al. Metabolic <u>Disposition Studies on Simvastatin, a Cholesterol-Lowering Prodrug.</u> Drug Metabolism and Disposition, Vol. 18, No. 2. pp. 138-145. 1990.
		. 44 F
		DATE CONSIDERED
		Twombs down duyent 3, 1997
	Į į	